Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2002 1
2004 6
2005 1
2007 3
2008 2
2009 2
2010 2
2011 1
2012 3
2013 5
2014 5
2015 6
2016 10
2017 10
2018 3
2019 7
2020 8
2021 8
2022 10
2023 14
2024 5
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49.8%) than the irbesartan group (-15.1%), resulting in a between-group relative reduction of 41% (least s …
At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly …
Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V; FIND-CKD Investigators. Heerspink HJL, et al. N Engl J Med. 2026 Aug 6;395(6):533-545. doi: 10.1056/NEJMoa2604625. Epub 2026 Jun 4. N Engl J Med. 2026. PMID: 42246672 Clinical Trial.
The mean annual rate of change in the eGFR from baseline to month 32 was -3.3 ml per minute per 1.73 m(2) (95% confidence interval [CI], -3.6 to -3.1) with finerenone and -4.0 ml per minute per 1.73 m(2) (95% CI, -4.3 to -3.8) with placebo (difference, 0.7; 95% CI, 0.3 to 1.1; …
The mean annual rate of change in the eGFR from baseline to month 32 was -3.3 ml per minute per 1.73 m(2) (95% confidence interval [CI], -3. …
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-110) was -2.7 mL/min per 1.73 m(2) per year versus -3.8 mL/min per 1.73 m(2) per year (difference 1.1 mL/min per 1.73 m(2) per year, 95% CI 0. …
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-11 …
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan group (P = 0.009), a response that was sustained through 108 weeks. At the time of the final analysis at week 108, there were no sign …
At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan …
Home-based exercise therapy for treating shoulder instability in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. A randomized trial.
Spanhove V, De Wandele I, Malfait F, Calders P, Cools A. Spanhove V, et al. Disabil Rehabil. 2023 Jun;45(11):1811-1821. doi: 10.1080/09638288.2022.2076932. Epub 2022 May 24. Disabil Rehabil. 2023. PMID: 35609204 Clinical Trial.
RESULTS: Significant main effects for time were observed for all questionnaires, except for the TSK (p = 0.12). Patients improved 240 and 325 points on the WOSI after 12 (p = 0.02) and 24 weeks (p = 0.001), respectively. Additionally, patients improved 8.6 po …
RESULTS: Significant main effects for time were observed for all questionnaires, except for the TSK (p = 0.12). Patients improved 240 …
Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis.
Bai Z, Bartelo N, Aslam M, Murphy EA, Hale CR, Blachere NE, Parveen S, Spolaore E, DiCarlo E, Gravallese EM, Smith MH; Accelerating Medicines Partnership RA/SLE Network; Frank MO, Jiang CS, Zhang H, Pyrgaki C, Lewis MJ, Sikandar S, Pitzalis C, Lesnak JB, Mazhar K, Price TJ, Malfait AM, Miller RE, Zhang F, Goodman S, Darnell RB, Wang F, Orange DE. Bai Z, et al. Sci Transl Med. 2024 Apr 10;16(742):eadk3506. doi: 10.1126/scitranslmed.adk3506. Epub 2024 Apr 10. Sci Transl Med. 2024. PMID: 38598614 Free PMC article.
Acute systemic macrophage depletion in osteoarthritic mice alleviates pain-related behaviors and does not affect joint damage.
Geraghty T, Ishihara S, Obeidat AM, Adamczyk NS, Hunter RS, Li J, Wang L, Lee H, Ko FC, Malfait AM, Miller RE. Geraghty T, et al. Arthritis Res Ther. 2024 Dec 20;26(1):224. doi: 10.1186/s13075-024-03457-9. Arthritis Res Ther. 2024. PMID: 39707543 Free PMC article.
METHODS: We depleted CSF1R + macrophages by treating male macrophage Fas-induced apoptosis (MaFIA) transgenic mice 8- or 16-weeks post destabilization of the medial meniscus (DMM) with AP20187 or vehicle control (10 mg/kg i.p., 1x/day for 5 days), or treating female MaFIA …
METHODS: We depleted CSF1R + macrophages by treating male macrophage Fas-induced apoptosis (MaFIA) transgenic mice 8- or 16-weeks post desta …
Muscle Strength, Muscle Mass and Physical Impairment in Women with hypermobile Ehlers-Danlos syndrome and Hypermobility Spectrum Disorder.
Coussens M, Lapauw B, Banica T, De Wandele I, Pacey V, Rombaut L, Malfait F, Calders P. Coussens M, et al. J Musculoskelet Neuronal Interact. 2022 Mar 1;22(1):5-14. J Musculoskelet Neuronal Interact. 2022. PMID: 35234154 Free PMC article.
Nevertheless, when both patient groups were compared to controls, physical functioning, maximal muscle strength and muscle strength endurance were significantly lower (all p<0.001), except for the hand flexors. CONCLUSION: Physical functioning, muscle strength, density …
Nevertheless, when both patient groups were compared to controls, physical functioning, maximal muscle strength and muscle strength enduranc …
RIN2 syndrome: Expanding the clinical phenotype.
Rosato S, Syx D, Ivanovski I, Pollazzon M, Santodirocco D, De Marco L, Beltrami M, Callewaert B, Garavelli L, Malfait F. Rosato S, et al. Am J Med Genet A. 2016 Sep;170(9):2408-15. doi: 10.1002/ajmg.a.37789. Epub 2016 Jun 8. Am J Med Genet A. 2016. PMID: 27277385 Review.
Here, we describe a 10th patient, the first patient of Caucasian origin and the oldest reported patient so far, who harbors the previously identified homozygous RIN2 mutation c.1878dupC (p. (Ile627Hisfs*7)). Besides the hallmark features, this patient also presents problem …
Here, we describe a 10th patient, the first patient of Caucasian origin and the oldest reported patient so far, who harbors the previously i …
99 results